Literature DB >> 19174735

Determinants of newly detected human papillomavirus infection in HIV-infected and HIV-uninfected injection drug using women.

Darcy F Phelan1, Stephen J Gange, Linda Ahdieh-Grant, Shruti H Mehta, Gregory D Kirk, Keerti Shah, Patti Gravitt.   

Abstract

BACKGROUND: We sought to identify factors associated with newly detected human papillomavirus (HPV) infection in a high-risk cohort of injection drug using women in Baltimore, MD.
METHODS: We studied 146 HIV-infected and 73 HIV-uninfected female participants in a 5-year prospective HIV natural history study. We examined the association of sexual and nonsexual risk factors and newly detected type-specific HPV infection as determined by consensus PCR between consecutive visits.
RESULTS: Newly detected HPV was more common among HIV-infected versus HIV-uninfected women (30% and 6%, respectively; P <0.01). Among the entire cohort, recent crack use (OR, 1.7; 95% CI, 1.1-2.6) and HIV infection/CD4 cell count were independent predictors for new HPV detection (HIV-uninfected as reference, OR, 4.6; 95% CI, 2.3-8.9, OR, 5.4; 95% CI, 2.8-10.3, and OR, 10.9; 95% CI, 5.5-21.7 for HIV-infected CD4 >500, 200-500, and <200, respectively). Among HIV-uninfected women, recent marijuana use was an independent predictor of newly detected HPV infection (OR, 3.5; 95% CI, 1.3-9.5).
CONCLUSIONS: Newly detected HPV clearly increased with greater immunosuppression in HIV-infected injection drug users. Larger studies of HIV-uninfected and infected high-risk individuals are needed to clarify the independent associations of crack and marijuana use with new (or reactivated) HPV infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19174735      PMCID: PMC2888629          DOI: 10.1097/OLQ.0b013e31818d3df3

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  29 in total

1.  Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland.

Authors:  D Vlahov; A Muñoz; J C Anthony; S Cohn; D D Celentano; K E Nelson
Journal:  Am J Epidemiol       Date:  1990-11       Impact factor: 4.897

Review 2.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 3.  The estimated direct medical cost of sexually transmitted diseases among American youth, 2000.

Authors:  Harrell W Chesson; John M Blandford; Thomas L Gift; Guoyu Tao; Kathleen L Irwin
Journal:  Perspect Sex Reprod Health       Date:  2004 Jan-Feb

4.  Prevalence, incidence, and type-specific persistence of human papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women.

Authors:  L Ahdieh; R S Klein; R Burk; S Cu-Uvin; P Schuman; A Duerr; M Safaeian; J Astemborski; R Daniel; K Shah
Journal:  J Infect Dis       Date:  2001-08-24       Impact factor: 5.226

5.  Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, 1988-1998.

Authors:  Kenrad E Nelson; Noya Galai; Mahboobeh Safaeian; Steffanie A Strathdee; David D Celentano; David Vlahov
Journal:  Am J Epidemiol       Date:  2002-10-01       Impact factor: 4.897

Review 6.  Human papillomavirus infection and disease in HIV-infected individuals.

Authors:  Michael E Hagensee; Jennifer E Cameron; Janet E Leigh; Rebecca A Clark
Journal:  Am J Med Sci       Date:  2004-07       Impact factor: 2.378

7.  Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine.

Authors:  Sue J Goldie; Michele Kohli; Daniel Grima; Milton C Weinstein; Thomas C Wright; F Xavier Bosch; Eduardo Franco
Journal:  J Natl Cancer Inst       Date:  2004-04-21       Impact factor: 13.506

8.  Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women.

Authors:  Howard Minkoff; Joseph G Feldman; Howard D Strickler; D Heather Watts; Melanie C Bacon; Alexandra Levine; Joel M Palefsky; Robert Burk; Mardge H Cohen; Kathryn Anastos
Journal:  J Infect Dis       Date:  2004-04-27       Impact factor: 5.226

9.  Latent Human Papillomavirus infection is comparable in the larynx and trachea.

Authors:  Allan L Abramson; May Nouri; Virginia Mullooly; Gene Fisch; Bettie M Steinberg
Journal:  J Med Virol       Date:  2004-03       Impact factor: 2.327

10.  Cervical human papillomavirus infection in the female population in Barcelona, Spain.

Authors:  Silvia de Sanjose; Rosa Almirall; Belen Lloveras; Rebeca Font; Mireia Diaz; Nubia Muñoz; Isabel Català; Chris J L M Meijer; Peter J F Snijders; Rolando Herrero; F Xavier Bosch
Journal:  Sex Transm Dis       Date:  2003-10       Impact factor: 2.830

View more
  12 in total

1.  HIV-positive women have higher risk of human papilloma virus infection, precancerous lesions, and cervical cancer.

Authors:  Gui Liu; Monisha Sharma; Nicholas Tan; Ruanne V Barnabas
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177

2.  Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand.

Authors:  Morgan Marks; Patti E Gravitt; Swati B Gupta; Kai-Li Liaw; Amha Tadesse; Esther Kim; Chailert Phongnarisorn; Virach Wootipoom; Pissimai Yuenyao; Charoen Vipupinyo; Somchai Sriplienchan; David D Celentano
Journal:  J Infect Dis       Date:  2011-09-29       Impact factor: 5.226

3.  Marijuana use is not associated with cervical human papillomavirus natural history or cervical neoplasia in HIV-seropositive or HIV-seronegative women.

Authors:  Gypsyamber D'Souza; Joel M Palefsky; Ye Zhong; Howard Minkoff; L Stewart Massad; Kathy Anastos; Alexandra M Levine; Michael Moxley; Xiao N Xue; Robert D Burk; Howard D Strickler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-02-16       Impact factor: 4.254

4.  Cervical screening within HIV care: findings from an HIV-positive cohort in Ukraine.

Authors:  Heather Bailey; Claire Thorne; Igor Semenenko; Ruslan Malyuta; Rostislav Tereschenko; Irina Adeyanova; Elena Kulakovskaya; Lyudmila Ostrovskaya; Liliana Kvasha; Mario Cortina-Borja; Claire L Townsend
Journal:  PLoS One       Date:  2012-04-24       Impact factor: 3.240

5.  Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status.

Authors:  Katharine J Looker; Minttu M Rönn; Patrick M Brock; Marc Brisson; Melanie Drolet; Philippe Mayaud; Marie-Claude Boily
Journal:  J Int AIDS Soc       Date:  2018-06       Impact factor: 5.396

6.  An audit of the cervical screening programme in the National Drug Treatment Centre (NDTC).

Authors:  Maeve Haran; John R Kelly; Liam Kennedy; Kieran Hennigan; Huma Farid; Cristina Herteu; Anna Kreisel; Shamus Salehin; Marie O' Sullivan; Shay Keating; Jo-Hanna Ivers; Mike Scully
Journal:  Ir J Med Sci       Date:  2021-01-15       Impact factor: 1.568

Review 7.  A Framework for Cervical Cancer Elimination in Low-and-Middle-Income Countries: A Scoping Review and Roadmap for Interventions and Research Priorities.

Authors:  Michelle B Shin; Gui Liu; Nelly Mugo; Patricia J Garcia; Darcy W Rao; Cara J Bayer; Linda O Eckert; Leeya F Pinder; Judith N Wasserheit; Ruanne V Barnabas
Journal:  Front Public Health       Date:  2021-07-01

8.  Genital Epstein Barr Virus is associated with higher prevalence and persistence of anal human papillomavirus in HIV-infected men on antiretroviral therapy.

Authors:  Sara Gianella; Christine C Ginocchio; Eric S Daar; Michael P Dube; Sheldon R Morris
Journal:  BMC Infect Dis       Date:  2016-01-25       Impact factor: 3.090

9.  Prevalence of and Risk Factors for Oral Human Papillomavirus Infection among HIV-Positive and HIV-Negative People Who Inject Drugs.

Authors:  Hilary A Robbins; Christina E Fennell; Maura Gillison; Weihong Xiao; Yingshi Guo; Alicia Wentz; Gregory D Kirk; Shruti H Mehta; Gypsyamber D'Souza
Journal:  PLoS One       Date:  2015-11-24       Impact factor: 3.240

10.  HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control.

Authors:  Karen Canfell; Jane J Kim; Shalini Kulasingam; Johannes Berkhof; Ruanne Barnabas; Johannes A Bogaards; Nicole Campos; Chloe Jennett; Monisha Sharma; Kate T Simms; Megan A Smith; Louiza S Velentzis; Marc Brisson; Mark Jit
Journal:  Papillomavirus Res       Date:  2019-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.